Loading clinical trials...

A Study of AK129 in Patients With Advanced Malignant Tumors | Clinical Trials | Clareo Health

RECRUITINGPHASE1

A Study of AK129 in Patients With Advanced Malignant Tumors

A Phase Ia/Ib, Open Label, Dose Escalation and Dose Extension Trial of Anti-PD-1 and LAG-3 Bispecific Antibody AK129 to Evaluate the Safety, Tolerability and Antitumor Efficacy in Patients With Advanced Malignant Tumors

NCT05645276•Akeso

View on ClinicalTrials.gov

Summary

A Phase Ia/Ib, open label, dose escalation and dose extension trial of Anti-PD-1 and LAG-3 bispecific antibody, AK129, to evaluate the safety, tolerability and antitumor efficacy in patients with advanced malignant tumors

Detailed Description

Anti Lymphocyte Activation Gene-3(LAG-3) combination therapy showed a preliminary antitumor signal in multiple solid tumors and hematologic tumor.LAG-3 targeted drug Relatilimab in a Phase 2/3 study comparing a combination of relatilimab and nivolumab to nivolumab alone in previously untreated patients with metastatic or unresectable melanoma.The combination therapy of Relatilimab with nivolumab showed a statistically significant and clinically significant progression-free survival(PFS) benefit compared to the nivolumab group, Because of this study, the FDA approved the combination therapy for first-line therapy of melanoma. AK129 is a humanized immunoglobulin G1(IgG1) bispecial antibody(BsAb), which can bind anti-programmed death receptor 1(PD-1) and LAG-3 at the same time, and block the interaction of PD-1/programmed cell death - ligand 1(PD-L1), LAG-3/ major histo-compatibility complex II(MHCII),etc. The aim of the first human, dose-escalation study of this investigational drug is to explore its safety, tolerability, and initial antitumor efficacy, and to evaluate its pharmacokinetic and pharmacokinetic characteristics to identify the appropriate dose and regimen.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. The subject must sign the written informed consent form(ICF) voluntarily.
•2. Aged ≥ 18 to ≤ 75 years.
•3. Eastern Cooperative Oncology Group(ECOG) performance status score of 0 or 1.
•4. Life expectancy≥ 3 months.
•5. Histologically or cytologically confirmed advanced solid tumors(dose-escalation phase) or selected tumor species(pharmacodynamic confirmation phase and dose-expansion phase);Patients with advanced metastatic malignancies who have failed first-line, or second-line, or third-line, or fourth-line standard therapy, or are ineligible for standard therapy, or cannot tolerate chemotherapy, or are unwilling to receive chemotherapy, or have no effective standard therapy.
•6. Pharmacodynamic confirmation phase and dose expansion phase: at least one measurable tumor lesion(RECIST v1.1, lymphoma according to Lugano 2014 evaluation criteria).A lesion from a site previously treated with radiotherapy or other local regional therapy is considered a non-target lesion unless there is definite progression of the lesion or the neoplastic nature of the lesion is confirmed by biopsy.
•7. Pharmacodynamic confirmation phase and dose extension phase: All subjects agree to provide archived or freshly obtained tumor tissue samples within 2 years prior to initial administration(formalin-fixed paraffin-embedded (FFPE) tissue wax blocks or approximately 10 unstained tumor tissue sections,and if there is archived tumor tissue within 6 months or 3 months, or freshly obtained tumor tissue, preferably recently obtained tumor tissue samples).
•8. The results of laboratory examination during the screening period indicate that the subjects have good organ function:1).Hematology (no supportive treatment of any component blood and cell growth factors were used within 7 days prior to the start of the study):Neutrophil absolute value(ANC)≥1.5×10\^9/L(solid tumors) or 1.0×10\^9/L(lymphoma);Platelet count≥100×10\^9/L(solid tumors) or 75×10\^9/L(lymphoma);haemoglobin≥90 g/L or ≥5.6 mmol/L. 2).Kidney:Serum creatinine(Cr)≤1.5×Upper limit of normal(ULN),or Creatinine clearance \*(CrCl) calculated value≥ 50 mL/min,CrCl was calculated by Cockcroft-Gault formula:CrCl (mL/min)={(140-age)×weight(kg)×F}/(SCr (mg/dL)×72),Male F=1,Female F=0.85,SCr=serum creatinine.3).Liver:Serum total bilirubin(TBil)≤1.5×ULN,Subjects with confirmed/suspected Gilbert disease,TBil ≤ 3× ULN;aspartate aminotransferase(AST) and alanine aminotransferase(ALT) ≤ 2.5×ULN,For subjects with liver metastasis or liver cancer,AST and ALT ≤ 5×ULN.4).Blood clotting function:Internationally standardized ratio(INR)≤ 1.5×ULN and activated partial thromboplastin time(APTT)≤ 1.5×ULN(If the subject is receiving anticoagulant therapy, the subject will receive a steady dose of anticoagulant and the coagulation parameters(prothrombin time(PT)/INR and APTT) will be within the expected range of anticoagulant therapy at the time of screening).5).Cardiac function:Left ventricular ejection fraction(LVEF)≥ 50%;Troponin protein T or I\<2×ULN.
•9. Fertile female subjects must undergo a negative serum pregnancy test within 3 days prior to initial medication.If a fertile female subject has sex with an unsterilized male partner, the subject must initiate a highly effective contraceptive method from screening and must agree to continue using these precautions until 120 days after the final administration of the study drug;Periodic abstinence, safe period contraception and extracorporeal ejaculation are not acceptable contraceptive methods;
•10. If an unsterilized male subject has sex with a fertile female partner, the subject must use an effective contraceptive method from the beginning of screening to within 120 days after the last dose.

Exclusion Criteria

•1. Active central nervous system metastasis.
•2. Subjects with uncontrolled pleural effusion, pericardial effusion, or abdominal effusion requiring repeated drainage(frequency greater than monthly).
•3. Patients with other active malignant tumors within 2 years prior to the first administration, except for locally curable tumor species and those who have been cured, such as squamous cell carcinoma of the skin, basal cell carcinoma of the skin, superficial bladder carcinoma, and carcinoma in situ of the breast.
•4. Known primary or secondary immunodeficiency,including human immunodeficiency virus(HIV) antibodies tested positive.
•5. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
•6. Known interstitial lung disease or non-infectious pneumonia requiring glucocorticoid therapy;Except for those caused by radiation therapy.
•7. Severe infections, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia, occur within 4 weeks prior to initial administration.
•8. Present with active infections(including active tuberculosis and active treponema pallidum) requiring systemic treatment, and have used systemic antibacterial, antiviral or antifungal drugs within 2 weeks prior to initial administration;Note: Antiviral drugs for viral hepatitis B are excluded.
•9. Subjects with active viral hepatitis B, non-active or asymptomatic hepatitis B virus(HBV) carriers(Hepatitis B surface antigen(HBsAg) positive) with HBV deoxyribonucleic acid(DNA)\>200IU/mL, and subjects with active viral hepatitis C.
•10. Have active or documented inflammatory bowel disease(e.g. Crohn's disease, ulcerative colitis), active diverticulitis.
+7 more criteria

Locations (1)

Cancer Hospital Chinese Academy of Medical Science

Beijing, Beijing Municipality, China

Key Dates

Start Date

March 2, 2023

Primary Completion Date

February 1, 2026

Completion Date

June 1, 2026

Last Updated

March 3, 2025

Enrollment

182

ESTIMATED participants

Conditions

Advanced Malignant Tumors(Stage IA-IB)

Interventions

AK129 IV infusion

DRUG

Contacts

Xiao Xu, MD, PhD

CONTACT

+86 (0760) 8987 3999 clinicaltrials@akesobio.com